A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

GLP-1 agonists, or glucagon-like peptide-1 agonists, function by mimicking the action of a natural hormone in the body that helps regulate blood sugar levels and digestion. Originally developed for ...

Why is an increase of nearly 48% in India’s coastline relevant to the UPSC exam? What is the significance of topics such as ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...

As India becomes the new and latest nation witnessing the for weight-loss drugs frenzy, Novo Nordisk’s Wegovy challenges Eli ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and b ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.